Program
vonoprazan
Also written as “TAK-438”, “Vonoprazan” and “Vonoprazan (Reference)”.
Its studies are mostly in Esophagitis · Stomach Ulcer · Gastroesophageal Reflux · Heartburn · Duodenal Ulcer, led by 5 companies.
Drug pageVonoprazan: every studyMany companies study it; this page follows only the 48 they lead. All 100 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 310 open or running | phase 4since Feb 8, 2016 | Sep 16, 2011 | none ahead |
| Phathom Pharmaceuticalsits history only | 142 open or running | phase 3since Oct 10, 2019 | Oct 10, 2019 | Oct 20, 2027phase 3 · NCT07752407 |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Nov 14, 2021 | Nov 14, 2021 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 1since Oct 14, 2024 | Oct 14, 2024 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Dec 9, 2025 | Dec 9, 2025 | none ahead |
Also a collaborator on its studies: Richmond Pharmacology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 34 studies since Sep 16, 2011.
- Jan 19, 2021Phase 1 study in Healthy ParticipantsPhathom Pharmaceuticals · NCT04729101 · 44 enrolled · United States
- Feb 12, 2021Phase 1 study in Helicobacter PyloriTakeda · NCT04753437 · 44 enrolled · China
- Mar 11, 2021Phase 2 study in HeartburnPhathom Pharmaceuticals · NCT04799158 · 458 enrolled · United States
- Nov 14, 2021Genuine Research Center, Egypt’s first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05135793 · 29 enrolled · Egypt
- Jan 4, 2022Phase 3 study in HeartburnPhathom Pharmaceuticals · NCT05195528 · 776 enrolled · United States
- Apr 18, 2022Phase 1 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT05343364 · 24 enrolled · United States
- May 4, 2022Phase 1 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT05366738 · 27 enrolled · United States
- Oct 24, 2023Phase 1 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT06106022 · 22 enrolled · United States
- Apr 25, 2024Phase 1 study in HeartburnPhathom Pharmaceuticals · NCT06391177 · 15 enrolled · United States
- Oct 14, 2024Hanlim Pharm.’s first study: phase 1 study in Stomach UlcerNew to Hanlim Pharm.Hanlim Pharm. · NCT06642987 · 30 enrolled · Korea, Republic of
- Feb 14, 2025Phase 1 study in Healthy VolunteersPhathom Pharmaceuticals · NCT06831344 · 25 enrolled · United States
- Feb 24, 2025Phase 2 study in Eosinophilic EsophagitisPhathom Pharmaceuticals · NCT06851559 · 95 enrolled · United States
- Dec 9, 2025Humanis Saglık Anonim Sirketi’s first study: phase 1 study in Erosive GastritisNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07278349 · 28 enrolled · Jordan
- Aug 3, 2026Phase 3 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT07752407 · 500 planned · United States
Ahead
- Oct 20, 2027Primary completion: phase 3 study in Gastroesophageal RefluxPhathom Pharmaceuticals · NCT07752407
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 48 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07752407Gastroesophageal Reflux · United States | 3 | Recruiting | Phathom Pharmaceuticals | Oct 20, 2027 | 500 |
| NCT07278349Erosive Gastritis · Jordan | 1 | Completed | Humanis Saglık Anonim Sirketi | Oct 4, 2025 | 28 |
| NCT06851559Eosinophilic Esophagitis · United States | 2 | Active, not recruiting | Phathom Pharmaceuticals | Sep 11, 2026 | 95 |
| NCT06831344Healthy Volunteers · United States | 1 | Completed | Phathom Pharmaceuticals | Apr 5, 2025 | 25 |
| NCT06642987Stomach Ulcer · Korea, Republic of | 1 | Completed | Hanlim Pharm. | Nov 3, 2023 | 30 |
| NCT06391177Heartburn · United States | 1 | Completed | Phathom Pharmaceuticals | Sep 13, 2024 | 15 |
| NCT06106022Gastroesophageal Reflux · United States | 1 | Completed | Phathom Pharmaceuticals | Apr 16, 2024 | 22 |
| NCT05366738Gastroesophageal Reflux · United States | 1 | Completed | Phathom Pharmaceuticals | Jul 1, 2022 | 27 |
| NCT05343364Gastroesophageal Reflux · United States | 1 | Completed | Phathom Pharmaceuticals | May 30, 2023 | 24 |
| NCT05195528Heartburn · United States | 3 | Completed | Phathom Pharmaceuticals | Nov 21, 2022 | 776 |
| NCT05135793Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Feb 2, 2021 | 29 |
| NCT04799158Heartburn · United States | 2 | Completed | Phathom Pharmaceuticals | Dec 16, 2021 | 458 |
| NCT04753437Helicobacter Pylori · China | 1 | Completed | Takeda | Sep 27, 2021 | 44 |
| NCT04729101Healthy Participants · United States | 1 | Completed | Phathom Pharmaceuticals | Jun 12, 2021 | 44 |
| NCT04558216Healthy Participants · United States | 1 | Withdrawn | Phathom Pharmaceuticals | Feb 7, 2021 | 0 |
| NCT04545944Healthy Volunteers · United States | 1 | Completed | Phathom Pharmaceuticals | Nov 13, 2020 | 20 |
| NCT04198363Helicobacter Pylori · China | 3 | Completed | Takeda | Nov 1, 2021 | 510 |
| NCT04167670Helicobacter Pylori Infection · United States, Bulgaria, Czechia and more | 3 | Completed | Phathom Pharmaceuticals | Mar 10, 2021 | 1,046 |
| NCT04124926Erosive Esophagitis · United States, Bulgaria, Czechia and more | 3 | Completed | Phathom Pharmaceuticals | Jul 29, 2021 | 1,027 |
| NCT03808493Japanese Healthy Adult Male · Japan | 1 | Completed | Takeda | Mar 12, 2019 | 48 |
| NCT03116841Esophagitis, Peptic · Japan | 4 | Completed | Takeda | Dec 20, 2017 | 3 |
| NCT03085836Healthy Participants · China | 1 | Completed | Takeda | Aug 17, 2017 | 33 |
| NCT03050359Duodenal Ulcer · China, Korea, Republic of, Philippines and more | 3 | Completed | Takeda | Mar 19, 2019 | 533 |
| NCT03050307Stomach Ulcer · China, Korea, Republic of, Philippines and more | 3 | Completed | Takeda | Feb 19, 2020 | 234 |
| NCT02954848Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Takeda | Feb 25, 2018 | 484 |
| NCT02892409Helicobacter Pylori · Korea, Republic of | 1 | Completed | Takeda | Apr 17, 2017 | 30 |
| NCT02774902Healthy Volunteers | 1 | Completed | Takeda | Sep 2010 | 16 |
| NCT02679508Esophagitis · Japan | 4 | Completed | Takeda | Mar 5, 2022 | 208 |
| NCT02388737Erosive Esophagitis · China, Korea, Republic of, Malaysia and more | 3 | Completed | Takeda | Dec 24, 2018 | 703 |
| NCT02388724Erosive Esophagitis · China, Korea, Republic of, Malaysia and more | 3 | Completed | Takeda | Jul 27, 2017 | 481 |
| NCT02141711Gastroesophageal Reflux · United Kingdom | 1 | Completed | Takeda | Feb 2009 | 48 |
| NCT02141698Dose Finding Study | 1 | Completed | Takeda | Feb 2008 | 73 |
| NCT02123953Dose Finding Study | 1 | Completed | Takeda | Mar 2009 | 60 |
| NCT02123927Ascending Single Dose Study | 1 | Completed | Takeda | Dec 2007 | 108 |
| NCT01630746Erosive Esophagitis · Japan | 3 | Completed | Takeda | Sep 2013 | 19 |
| NCT01568398Stomach Ulcer · Japan | 3 | Completed | Takeda | Aug 2013 | 27 |
| NCT01568385Stomach Ulcer · Japan | 3 | Completed | Takeda | Sep 2013 | 30 |
| NCT01505127H. Pylori Infection · Japan | 3 | Completed | Takeda | Jun 2013 | 650 |
| NCT01474369Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Takeda | Feb 2013 | 827 |
| NCT01459367Erosive Esophagitis · Japan | 3 | Completed | Takeda | Mar 2013 | 607 |
| NCT01456260Stomach Ulcer · Japan | 3 | Completed | Takeda | 406 | |
| NCT01456247Stomach Ulcer · Japan | 3 | Completed | Takeda | Oct 2013 | 439 |
| NCT01452776Erosive Esophagitis · Japan | 3 | Completed | Takeda | Jul 2013 | 305 |
| NCT01452763Stomach Ulcer · Japan | 3 | Completed | Takeda | Apr 2013 | 621 |
| NCT01452750Stomach Ulcer · Japan | 3 | Completed | Takeda | Jun 2013 | 642 |
| NCT01452724Duodenal Ulcer · Japan | 3 | Completed | Takeda | Feb 2013 | 372 |
| NCT01452711Stomach Ulcer · Japan | 3 | Completed | Takeda | Dec 2012 | 482 |
| NCT01452698Erosive Esophagitis · Japan | 3 | Completed | Takeda | Aug 2012 | 409 |
How it is read
Names in the registry
- “TAK-438”, 32 entries
- “Vonoprazan”, 20 entries
- “Vonoprazan (Reference)”, 1 entry
- “Vonoprazan Tablets”, 1 entry
- “VOQUEZNA® Tablets”, 1 entry
Conditions, from the studies’ own filings
- Esophagitis, 9 studies
- Stomach Ulcer, 9 studies
- Gastroesophageal Reflux, 7 studies
- Heartburn, 3 studies
- Duodenal Ulcer, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.